Adherence to risk minimization measures for alemtuzumab use in multiple sclerosis: a drug utilization study in four European countries.

de Keijzer C, E J-Y, Yang Q, Gitonga R, Hiller D, Jurgensen S, Salloum N, Cunha-Santos J, Hoogewys-Cynober E, Vinet L, et al.

Ther Adv Neurol Disord. 2026; 19:17562864261444676. PMID: 42179973. Abstract